We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Sublocade concentration, pipeline setbacks and legal exposure temper the benefits of stronger profitability.
Indivior Pharmaceuticals (INDV - Free Report) enters the second half of 2026 with accelerating Sublocade demand, a lower cost base and higher earnings guidance. The company is translating commercial momentum into stronger profitability and cash generation.
The trade-off is concentration. Sublocade produces most revenues, the internal pipeline has narrowed and legal exposure remains. Valuation also asks investors to balance improving fundamentals against a premium sales multiple.
INDV’s Sublocade Engine Is Still Accelerating
Sublocade generated a record $253 million in second-quarter 2026 revenues, up 21% year over year. U.S. dispense volume increased 18%, while new patient starts reached a record 32,816.
Management raised 2026 Sublocade revenue guidance to $1.01-$1.05 billion from $950-$990 million. Alkermes plc (ALKS - Free Report) also participates in addiction treatment through Vivitrol, a once-monthly injectable approved for prevention of relapse to opioid dependence after detoxification, providing another public-company reference point in long-acting addiction therapy.
Indivior’s Leaner Cost Base Lifts Earnings
Adjusted operating expenses fell 33% year over year to $112 million in the second quarter. Adjusted EBITDA increased 111% to $186 million as Indivior combined higher revenues with a leaner expense base.
The company raised its 2026 adjusted EBITDA outlook to $700-$740 million from $620-$660 million. Cash and investments also increased to $249 million at quarter-end from $201 million on March 31, 2026.
INDV Valuation Balances Growth With a Premium
INDV trades at 3.29X forward 12-month sales per share, above the 2.02X multiple for its Zacks sub-industry and its own five-year median of 2.7X. The shares have also gained 57.1% in the past year.
Earnings-based measures look different. INDV carries a forward P/E of 10.3 and a PEG ratio of 0.43, while projected current-fiscal-year EPS growth stands at 46.4%. That combination makes the valuation picture mixed rather than uniformly expensive.
Sublocade generates around 70% of Indivior’s total revenues, leaving financial performance sensitive to prescription growth, reimbursement and competition. The company decided not to advance INDV-6001 into phase III and halted internal development of INDV-2000 after disappointing phase II data.
The proposed merger with Supernus Pharmaceuticals (SUPN - Free Report) could broaden the business if completed. The combined company is expected to have 11 marketed medicines across psychiatry, neurology and addiction, while also advancing Supernus’ pipeline programs.
INDV’s Legal Overhang Keeps Caution in the Mix
Indivior continues to face opioid-related, antitrust and other litigation. It also remains subject to obligations under its Department of Justice resolution agreement through 2027.
Legal outcomes are difficult to predict and could bring additional settlements, fines or operating restrictions. Those risks remain relevant even as Sublocade growth, cost reductions and higher earnings improve the operating picture.
INDV’s Scores Favor Quality but Not Complacency
INDV’s fundamentals support a constructive near-term view, but the premium sales valuation, product concentration and legal exposure keep the risk-reward balanced. Sublocade growth and cost discipline are lifting earnings, while the pipeline setbacks leave less internal diversification.
INDV currently carries a Zacks Rank #2 (Buy) and a VGM Score of A, with a Value Score of B, Growth Score of A and Momentum Score of B. Under the Zacks framework, a top-two Zacks Rank paired with A or B Style Scores is favorable for near-term stock selection. The scores support consideration of INDV without removing its company-specific risks.
View the Zacks #1 Rank List
Image: Bigstock
Should Investors Buy INDV as Sublocade Growth Meets Rising Risks?
Key Takeaways
Indivior Pharmaceuticals (INDV - Free Report) enters the second half of 2026 with accelerating Sublocade demand, a lower cost base and higher earnings guidance. The company is translating commercial momentum into stronger profitability and cash generation.
The trade-off is concentration. Sublocade produces most revenues, the internal pipeline has narrowed and legal exposure remains. Valuation also asks investors to balance improving fundamentals against a premium sales multiple.
INDV’s Sublocade Engine Is Still Accelerating
Sublocade generated a record $253 million in second-quarter 2026 revenues, up 21% year over year. U.S. dispense volume increased 18%, while new patient starts reached a record 32,816.
Management raised 2026 Sublocade revenue guidance to $1.01-$1.05 billion from $950-$990 million. Alkermes plc (ALKS - Free Report) also participates in addiction treatment through Vivitrol, a once-monthly injectable approved for prevention of relapse to opioid dependence after detoxification, providing another public-company reference point in long-acting addiction therapy.
Indivior’s Leaner Cost Base Lifts Earnings
Adjusted operating expenses fell 33% year over year to $112 million in the second quarter. Adjusted EBITDA increased 111% to $186 million as Indivior combined higher revenues with a leaner expense base.
The company raised its 2026 adjusted EBITDA outlook to $700-$740 million from $620-$660 million. Cash and investments also increased to $249 million at quarter-end from $201 million on March 31, 2026.
INDV Valuation Balances Growth With a Premium
INDV trades at 3.29X forward 12-month sales per share, above the 2.02X multiple for its Zacks sub-industry and its own five-year median of 2.7X. The shares have also gained 57.1% in the past year.
Earnings-based measures look different. INDV carries a forward P/E of 10.3 and a PEG ratio of 0.43, while projected current-fiscal-year EPS growth stands at 46.4%. That combination makes the valuation picture mixed rather than uniformly expensive.
Indivior Pharmaceuticals Inc. Price and Consensus
Indivior Pharmaceuticals Inc. price-consensus-chart | Indivior Pharmaceuticals Inc. Quote
Indivior’s Pipeline Setbacks Raise Concentration Risk
Sublocade generates around 70% of Indivior’s total revenues, leaving financial performance sensitive to prescription growth, reimbursement and competition. The company decided not to advance INDV-6001 into phase III and halted internal development of INDV-2000 after disappointing phase II data.
The proposed merger with Supernus Pharmaceuticals (SUPN - Free Report) could broaden the business if completed. The combined company is expected to have 11 marketed medicines across psychiatry, neurology and addiction, while also advancing Supernus’ pipeline programs.
INDV’s Legal Overhang Keeps Caution in the Mix
Indivior continues to face opioid-related, antitrust and other litigation. It also remains subject to obligations under its Department of Justice resolution agreement through 2027.
Legal outcomes are difficult to predict and could bring additional settlements, fines or operating restrictions. Those risks remain relevant even as Sublocade growth, cost reductions and higher earnings improve the operating picture.
INDV’s Scores Favor Quality but Not Complacency
INDV’s fundamentals support a constructive near-term view, but the premium sales valuation, product concentration and legal exposure keep the risk-reward balanced. Sublocade growth and cost discipline are lifting earnings, while the pipeline setbacks leave less internal diversification.
INDV currently carries a Zacks Rank #2 (Buy) and a VGM Score of A, with a Value Score of B, Growth Score of A and Momentum Score of B. Under the Zacks framework, a top-two Zacks Rank paired with A or B Style Scores is favorable for near-term stock selection. The scores support consideration of INDV without removing its company-specific risks.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.